The CONSORT statement checklist in allergen-specific immunotherapy: A GA 2LEN paper

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 12, 2009, Pages 1737-1745

  Bousquet, P J ^a   Brozek, J ^b   Bachert, C ^c   Bieber, T ^d   Bonini, S ^e   Burney, P ^f   Calderon, M ^h   Canonica, G W ^g   Compalati, E ^g   Daures, J P ^a   Delgado, L ^h   Demoly, P ⁱ   Dahl, R ^j   Durham, S R ^f   Kowalski, M L ^k   Malling, H J ^l   Merk, H ^m   Papadopoulos, N ⁿ   Passalacqua, G ^g   Simon, H U ^o   Worms, M ^p   Wahn, U ^p   Zuberbier, T ^p   Schunemann H J ^b   Bousquet, J ⁱ   more..

^a Groupe Hospitalo Universtaire Caremeau   (France)

^b MCMASTER UNIVERSITY   (Canada)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF BONN   (Germany)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF GENOA   (Italy)

^h University of Porto   (Portugal)

ⁱ INSERM   (France)

^j AARHUS UNIVERSITY   (Denmark)

^k UNIVERSITY OF LODZ   (Poland)

^l Rigshospitalet   (Denmark)

^m UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁿ UNIVERSITY OF ATHENS   (Greece)

^o UNIVERSITY OF BERN   (Switzerland)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Consort; Ga 2len; Randomized controlled trial; Specific immunotherapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; PLACEBO; VACCINE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL RESEARCH; HEALTH CARE PERSONNEL; HUMAN; IMMUNOTHERAPY; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN TEST; TREATMENT WITHDRAWAL;

ALLERGENS; DOUBLE-BLIND METHOD; HUMANS; IMMUNOTHERAPY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE STANDARDS;

EID: 70449133821     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.02232.x     Document Type: Article

References (47)

1. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009 64 : 669 677.
2. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007 62 : 317 324.
3. Committee for medicinal products for human use (CPMP). Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. London, 20 November, 2008.
4. Lorenz AR, Luttkopf D, Seitz R, Vieths S. The regulatory system in europe with special emphasis on allergen products. Int Arch Allergy Immunol 2008 147 : 263 275.
5. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609 613. (Pubitemid 28380142)
6. Bausch B, Spaar A, Kleijnen J, Puhan MA. Quality of randomised trials in chronic obstructive pulmonary disease. Eur Respir J 2009 [Epub ahead of print].
7. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996 276 : 637 639. (Pubitemid 26278070)
8. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001 357 : 1191 1194. (Pubitemid 32378696)
9. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008 148 : 295 309. (Pubitemid 351665487)
10. Van Cauwenberge P, Watelet JB, Van Zele T, Bousquet J, Burney P, Zuberbier T. Spreading excellence in allergy and asthma: the GA2 LEN (Global Allergy and Asthma European Network) project. Allergy 2005 60 : 858 864.
11. Bousquet J, Burney PG, Zuberbier T, Cauwenberge PV, Akdis CA, Bindslev-Jensen C et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy 2009 64 : 969 977.
12. Bousquet PJ, Chatzi L, Jarvis D, Burney P. Assessing skin prick tests reliability in ECRHS-I. Allergy 2007 63 : 341 346.
13. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008 63 (SUPPL. 86 8 160.
14. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008 31 : 143 178.
15. Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C et al. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy 2008 63 : 1550 1558.
16. Committee for medicinal products for human use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. 20 November, 2008.
17. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 81 (5 Pt 1 401 405.
18. Puhan M, Schünemann H. How to increase the value of randomized trials in COPD research. Eur Respir J 2009 34 : 552 558.
19. Gotzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008 63 : 646 659.
20. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008 63 : 310 326.
21. Bousquet PJ, Demoly P, Passalacqua G, Canonica GW, Bousquet J. Immunotherapy: clinical trials - optimal trial and clinical outcomes. Curr Opin Allergy Clin Immunol 2007 7 : 561 566.
22. BMJ group. Grazax for hay fever? Drug Ther Bull 2008 46 : 9 10.
23. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy 2007 37 : 772 779. (Pubitemid 46646783)
24. Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med 2007 101 : 1885 1889.
25. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008 63 : 1624 1629.
26. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2008 100 : 482 489.
27. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004 59 : 45 53. (Pubitemid 38167951)
28. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004 114 : 831 837.
29. Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006 61 : 849 854.
30. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004 59 : 491 497.
31. Bousquet J, Maasch HJ, Hejjaoui A, Skassa-Brociek W, Wahl R, Dhivert H et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989 84 (4 Pt 1 546 556.
32. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007 62 : 1023 1028.
33. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006 4 : 69.
34. Guyatt G, Schunemann H. How can quality of life researchers make their work more useful to health workers and their patients? Qual Life Res 2007 16 : 1097 1105.
35. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 118 : 434 440.
36. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 117 : 802 809.
37. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007 120 : 1338 1345.
38. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006 61 : 185 190. (Pubitemid 43381828)
39. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006 61 : 843 848.
40. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study [in process citation]. Allergy 1999 54 : 249 260.
41. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007 18 : 47 57.
42. Lombardi C, Gargioni S, Cottini M, Canonica GW, Passalacqua G. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008 63 : 375 376.
43. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999 20 : 109 117.
44. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004 141 : 781 788.
45. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr., Bock SA, Branum A et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006 117 : 391 397.
46. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006 61 (SUPPL. 82 1 20.
47. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005 294 : 2203 2209.